Revisiting the need for vaccine prevention of late-onset neonatal group b streptococcal disease

Pediatric Infectious Disease Journal

Volumn 27, Issue 12, 2008, Pages 1057-1064

  Jordan, Hannah T ^a,b   Farley, Monica M ^c   Craig, Allen ^d   Mohle Boetani, Janet ^e   Harrison, Lee H ^f   Petit, Susan ^g   Lynfield, Ruth ^h   Thomas, Ann ⁱ   Zansky, Shelley ^j   Gershman, Kenneth ^k   Albanese, Bernadette A ^l   Schaffner, William ^m   Schrag, Stephanie J ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c EMORY UNIVERSITY   (United States)

^d TENNESSEE DEPARTMENT OF HEALTH   (United States)

^e California Department of Public Health   (United States)

^f JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^g Connecticut Department of Health ^*  (United States)

^h MINNESOTA DEPARTMENT OF HEALTH   (United States)

ⁱ OREGON PUBLIC HEALTH DIVISION   (United States)

^j NEW YORK STATE DEPARTMENT OF HEALTH   (United States)

^k Colorado Department Public Health and Environment ^*  (United States)

^l NEW MEXICO DEPARTMENT OF HEALTH   (United States)

^m VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Group B streptococcus; neonatal; surveillance; vaccine

Indexed keywords

TRIPLE VACCINE; STREPTOCOCCUS VACCINE;

ARTICLE; BACTERIUM ISOLATION; FATALITY; FEMALE; GESTATIONAL AGE; GROUP B STREPTOCOCCAL INFECTION; GROUP B STREPTOCOCCAL MENINGITIS; HEALTH SURVEY; HUMAN; INCIDENCE; INFANT; INFECTION PREVENTION; MAJOR CLINICAL STUDY; MALE; NEWBORN; NEWBORN INFECTION; ONSET AGE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; SEROTYPE; STREPTOCOCCUS AGALACTIAE; TREND STUDY; UNITED STATES; VACCINATION; CLINICAL TRIAL; CONFIDENCE INTERVAL; ISOLATION AND PURIFICATION; MULTICENTER STUDY; NEWBORN DISEASE; NEWBORN SCREENING; PREGNANCY; RISK FACTOR; STATISTICS; STREPTOCOCCUS INFECTION;

CONFIDENCE INTERVALS; FEMALE; GESTATIONAL AGE; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; INFANT, NEWBORN, DISEASES; MALE; NEONATAL SCREENING; POPULATION SURVEILLANCE; PREGNANCY; RISK FACTORS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; UNITED STATES; VACCINATION;

EID: 58149397736     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e318180b3b9     Document Type: Article

References (48)

1. Baker CJ, Barrett FF, Gordon RC, Yow MD. Suppurative meningitis due to streptococci of Lance?eld group B: a study of 33 infants. J Pediatr. 1973;82:724-729.
2. Franciosi RA, Knostman JD, Zimmerman RA. Group B streptococcal neonatal and infant infections. J Pediatr. 1973;82:707-718.
3. McCracken GH. Group B streptococci: the new challenge in neonatal infections. J Pediatr. 1973;82:703-706.
4. Barton LL, Feigin RD, Lins R. Group B beta hemolytic streptococcal meningitis in infants. J Pediatr. 1973;82:719-723.
5. Schrag SJ, Zywicki S, Farley MM, et al. Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis. N Engl J Med. 2000; 342:15-20.
6. Prevention of perinatal group B streptococcal disease: a public health perspective. Centers for Disease Control and Prevention. MMWR Recomm Rep. 1996;45(RR-7):1-24.
7. Schrag SS, Gorwitz RR, Fultz-Butts KK, Schuchat AA. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep. 2002;51(RR-11):1-22.
8. Centers for Disease Control and Prevention (CDC). Diminishing racial disparities in early-onset neonatal group B streptococcal disease-United States, 2000-2003. MMWR Morb Mortal Wkly Rep. 2004;53:502-505.
9. Centers for Disease Control and Prevention (CDC). Decreasing inci- dence of perinatal group B streptococcal disease-United States, 1993- 1995. MMWR Morb Mortal Wkly Rep. 1997;46:473-477.0
10. Davis RL, Hasselquist MB, Cardenas V, et al. Introduction of the new Centers for Disease Control and Prevention group B streptococcal prevention guideline at a large West Coast health maintenance organi- zation. Am J Obstet Gynecol. 2001;184:603-610.
11. Schrag SJ, Zell ER, Lyn?eld R, et al. A population-based comparison of strategies to prevent early-onset group B streptococcal disease in neo- nates. N Engl J Med. 2002;347:233-239.
12. Schuchat A, Oxtoby M, Cochi S, et al. Population-based risk factors for neonatal group B streptococcal disease: results of a cohort study in metropolitan Atlanta. J Infect Dis. 1990;162:672-677.
13. Lin FY, Weisman LE, Troendle J, Adams K. Prematurity is the major risk factor for late-onset group B streptococcus disease. J Infect Dis. 2003;188:267-271.
14. Godambe S, Shah PS, Shah V. Breast milk as a source of late onset neonatal sepsis. Pediatr Infect Dis J. 2005;24:381-382.
15. Olver WJ, Bond DW, Boswell TC, Watkin SL. Neonatal group B streptococcal disease associated with infected breast milk. Arch Dis Child Fetal Neonatal Ed. 2000;83:F48-F49.
16. Kotiw M, Zhang GW, Daggard G, Reiss-Levy E, Tapsall JW, Numa A. Lateonset and recurrent neonatal group B streptococcal disease associ- ated with breast-milk transmission. Pediatr Dev Pathol. 2003;6:251- 256.
17. Kenny JF. Recurrent group B streptococcal disease in an infant associ- ated with the ingestion of infected mother's milk. J Pediatr. 1977;91: 158-159.
18. Schreiner RL, Coates T, Shackelford PG. Possible breast milk transmission of group B streptococcal infection. J Pediatr. 1977;91:159.
19. Boyer KM, Vogel LC, Gotoff SP, Gadzala CA, Stringer J, Maxted WR. Nosocomial transmission of bacteriophage type 7/11/12 group B strep- tococci in a special care nursery. Am J Dis Child. 1980;134:964-966.
20. Easmon CS, Hastings MJ, Clare AJ, et al. Nosocomial transmission of group B streptococci. BMJ. 1981;283:459-461.
21. Noya FJ, Rench MA, Metzger TG, Colman G, Naidoo J, Baker CJ. Unusual occurrence of an epidemic of type Ib/c group B streptococcal sepsis in a neonatal intensive care unit. J Infect Dis. 1987;155:1135- 1144.
22. Centers for Disease Control and Prevention (CDC). Early-onset and late-onset neonatal group B streptococcal disease-United States, 1996- 2004. MMWR Morb Mortal Wkly Rep. 2005;54:1205-1208.
23. Mohle-Boetani JC, Schuchat A, Plikaytis BD, Smith JD, Broome CV. Comparison of prevention strategies for neonatal group B streptococcal infection. A population-based economic analysis. JAMA. 1993;270:1442-1448.
24. Baker CJ, Edwards MS. Group B streptococcal conjugate vaccines. Arch Dis Child. 2003;88:375-378.
25. Maione D, Margarit I, Rinaudo CD, et al. Identi?cation of a universal group B streptococcus vaccine by multiple genome screen. Science. 2005;309:148-150.
26. Baker CJ, Rench MA, McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine. 2003;21:3468-3472.
27. Baker CJ, Rench MA, Paoletti LC, Edwards MS. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vac- cine in healthy adults. Vaccine. 2007;25:55.
28. Stratton KR, Lawrence R, eds. Vaccines for the 21st Century: A Tool for Decision Making. Washington, DC: National Academy Press; 2000:476.
29. Zangwill KM, Schuchat A, Wenger JD. Group B streptococcal disease in the United States, 1990: report from a multistate active surveillance system. MMWR CDC Surveill Summ. 1992;41:25-32.
30. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Kirmeyer S. Births: ?nal data for 2004. Natl Vital Stat Rep. 2006;55:1-101.
31. Slotved HC, Elliott J, Thompson T, Konradsen HB. Latex assay for serotyping of group B Streptococcus isolates. J Clin Microbiol. 2003; 41:4445-4447.
32. Heard SR, Mawn JA. New phenotypic typing scheme for group B streptococci. J Clin Pathol. 1993;46:145-148.
33. National Committee for Clinical Laboratory Standards (NCCLS). NCCLS Performance Standards for Antimicrobial Susceptibility Testing. Twelfth Informational Supplement: M100-12 (2002) M2-A7 and M7-A5.
34. Martin JA, Hamilton BE, Sutton PD, Ventura SJ, Menacker F, Munson ML. Births: ?nal data for 2003. Natl Vital Stat Rep. 2005;54:1-116.
35. Zell ER. Using multiple imputation to improve race-speci?c disease rate reporting in a national active surveillance system. In: 2006 Proceedings of the American Statistical Association, Section on Statistics in Epide- miology -on CD-ROM-. Alexandria, VA: American Statistical Association; 2006.6
36. Edwards MS, Rench MMA, Haffar AA, Murphy MA, Desmond MM, Baker CJ. Long-term sequelae of group B streptococcal meningitis in infants. J Pediatr. 1985;106:717-722.
37. Kasper D, Paoletti L, Wessels M, et al. Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine. J Clin Invest. 1996;98:2308-2314.
38. Harrison LH, Elliott JA, Dwyer DM, et al. Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis. 1998;177:998-1002.
39. Lin FY, Azimi PH, Weisman LE, et al. Antibiotic susceptibility pro?les for group B streptococci isolated from neonates, 1995-1998. Clin Infect Dis. 2000;31:76-79.
40. Zaleznik DF, Rench MA, Hillier S, et al. Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups. Clin Infect Dis. 2000;30:276-281.
41. Hillier SL, Baker CJ, Ferrieri P, Krohn MA. Could a vaccine against group B streptococcus protect against vaginal colonization? In: Program and Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology; 2002:239:. Abstract G-154.
42. Simoes JA, Aroutcheva AA, Heimler I, Faro S. Antibiotic resistance patterns of group B streptococcal clinical isolates. Infect Dis Obstet Gynecol. 2004;12:1-8.
43. Andrews JI, Diekema DJ, Hunter SK, et al. Group B streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the Western Hemisphere. Am J Obstet Gynecol. 2000;183:859-862.
44. Morales WJ, Dickey SS, Bornick P, Lim DV. Change in antibiotic resistance of group B streptococcus: impact on intrapartum management. Am J Obstet Gynecol. 1999;181:310-314.
45. Pearlman MD, Pierson CL, Faix RG. Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin. Obstet Gynecol. 1998;92:258-261.
46. Hickman ME, Rench MA, Ferrieri P, Baker CJ. Changing epidemiology of group B streptococcal colonization. Pediatrics. 1999;104(2 Pt 1):203- 209.
47. Newton ER, Butler MC, Shain RN. Sexual behavior and vaginal colo- nization by group B streptococcus among minority women. Obstet Gynecol. 1996;88(4 Pt 1):577-582.
48. Stapleton RD, Kahn JM, Evans LE, Critchlow CW, Gardella CM. Risk factors for group B streptococcal genitourinary tract colonization in pregnant women. Obstet Gynecol. 2005;106:1246-1252.